Navigation Links
Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 29th Annual J.P. Morgan Healthcare Conference, being held January 10-13, 2011 at the Westin St. Francis Hotel in San Francisco. Mr. Bentsur's presentation is scheduled to take place on Tuesday, January 11th, at 4:00 p.m. PST (7:00 p.m. EST).

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrat
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced the ... Strategic Business Report" report to their offering. ... Supplies in US$ Thousands by the following Product Segments: Media, Sera, ... the US, Canada , Japan ... and Latin America . Annual estimates and forecasts ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... Oct. 2 The Matan Companies has teamed up ... for the development of the National Cancer Institute,s 330,000 ... Research Park in Frederick, Maryland. The state-of-the art ... construction immediately and is slated for delivery in mid ...
... Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., ... Officer. This position will be formally held by Dr. Fung ... Chapter 11 of the U.S. Bankruptcy Code or earlier, if ... interim, Dr. Fung will work as an independent consultant. ...
... J.D. , has opened Stipkala LLC,s new office in Cincinnati, ... Stipkala LLC is an intellectual property law firm with locations ... Guttman has more than nine years of patent law experience, ... entering patent law, Dr. Guttman acquired over ten years of ...
Cached Biology Technology:Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 2Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 3Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 4Vermillion Announces Return of Eric Fung, M.D., Ph.D. 2Vermillion Announces Return of Eric Fung, M.D., Ph.D. 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... HOUSTON -- ( Aug. 19, 2014 ) -- Scientists ... how to pick up and transfer single cells using ... tweaked slightly. They describe this engineering feat and preliminary ... Journal of the American Chemical Society . , "Studying ... frontier in current biomedical research," said nanomedicine department. faculty ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2
... marine vibrio bacteria discovered in the last five years, can ... in Edinburgh. , The most common disease of vibrios is ... fatality in humans. Recent interest in this genus of bacteria ... from seawater and marine animals. , New species have been ...
... professor of molecular and human genetics at Baylor College of ... in bacteria stressed by starvation, sometimes resulting in a rare ... a report in the current issue of the journal Molecular ... happens but also show that this only occurs at a ...
... Scientists from the Public Health Agency of Canada - ... of Infectious Diseases - have developed vaccines against the ... be effective in non-human primates. , In a study ... Heinz Feldmann and Dr. Steven Jones of PHAC's National ...
Cached Biology News:Stressed cells spark DNA repair missteps and speed evolution 2Researchers report breakthrough against world’s deadliest viruses 2
Plasmid expressing PLAP reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
... These 2800mL wide mouth PYREX Fernbach-style ... the center of the flask bottom to ... These triple baffled flasks have a Delong-style ... stainless steel closures. For plastic closures see ...
Biology Products: